Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.

Autor: Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut, USA., Borate U; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Pollyea DA; Division of Hematology, Department of Medicine, University of Colorado, Aurora, Colorado, USA., Brunner AM; Center for Leukemia, Massachusetts General Hospital, Boston, Massachusetts, USA., Roncolato F; Department of Hematology, St George Hospital, Sydney, New South Wales, Australia., Garcia JS; Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Filshie R; Department of Hematology, St Vincent's Hospital, Melbourne, Victoria, Australia., Odenike O; Section of Hematology/Oncology, University of Chicago Medicine and Comprehensive Cancer Center, Chicago, Illinois, USA., Watson AM; Department of Hematology, Liverpool Hospital, Sydney, New South Wales, Australia., Krishnadasan R; Department of Hematology, University of Arizona Cancer Center, Tucson, Arizona, USA., Bajel A; Department of Clinical Hematology, Peter MacCallum Cancer Center and The Royal Melbourne Hospital, Melbourne, Victoria, Australia., Naqvi K; Research and Development, Genentech Inc, South San Francisco, California, USA., Zha J; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Cheng WH; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Zhou Y; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Hoffman D; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Harb JG; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Potluri J; Research and Development, AbbVie Inc, North Chicago, Illinois, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2023 Feb; Vol. 98 (2), pp. 272-281. Date of Electronic Publication: 2022 Nov 10.

Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

Autor: Silvestri G; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Trotta R; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland., Stramucci L; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Ellis JJ; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Harb JG; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Neviani P; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Wang S; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland., Eisfeld AK; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Walker CJ; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Zhang B; Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California., Srutova K; Institute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic., Gambacorti-Passerini C; Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy., Pineda G; Department of Health Sciences, School of Health and Human Services, National University, San Diego, California., Jamieson CHM; Department of Medicine and Moores Cancer Center, University of California, San Diego, La Jolla, California., Stagno F; Division of Hematology and Unit of Medical Oncology, A.O.U. 'Policlinico-Vittorio Emanuele', University of Catania, Catania, Italy., Vigneri P; Division of Hematology and Unit of Medical Oncology, A.O.U. 'Policlinico-Vittorio Emanuele', University of Catania, Catania, Italy., Nteliopoulos G; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom., May PC; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom., Reid AG; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom., Garzon R; Department of Molecular Virology Immunology and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Roy DC; Department of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada., Moutuou MM; Department of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada., Guimond M; Department of Hematology and Cellular Therapy Laboratory, Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada., Hokland P; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Deininger MW; Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Fitzgerald G; Center for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland., Harman C; Center for Advanced Fetal Care University, University of Maryland School of Medicine, Baltimore, Maryland., Dazzi F; Division of Cancer Studies, Rayne Institute, King's College London, London, United Kingdom., Milojkovic D; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom., Apperley JF; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom., Marcucci G; Division of Hematopoietic Stem Cell and Leukemia Research, City of Hope National Medical Center, Duarte, California., Qi J; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Polakova KM; Institute of Hematology and Blood Transfusion, University of Prague, Prague, Czech Republic., Zou Y; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Fan X; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Baer MR; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland., Calabretta B; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Perrotti D; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland. dperrotti@som.umaryland.edu.; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.; Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom.; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland.

Publikováno v: Blood cancer discovery [Blood Cancer Discov] 2020 Jul; Vol. 1 (1), pp. 48-67.

Dosimetric evaluation of target coverage as a predictor of local failure following stereotactic body radiation therapy for spinal tumors.

Autor: Jawad MS; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Zhou J; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Harb JG; Department of Neuroradiology, William Beaumont Hospital, Royal Oak, MI, USA., Wilkinson JB; Department of Radiation Oncology, Willis-Knighton Health System/LSU Health Science Center, Shreveport, LA, USA., Prausa SK; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Wloch J; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Krauss DJ; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Fahim D; Department of Neurosurgery, William Beaumont Hospital, Royal Oak, MI, USA., Yan D; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA., Grills IS; Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, MI, USA.

Publikováno v: Journal of radiosurgery and SBRT [J Radiosurg SBRT] 2015; Vol. 3 (3), pp. 225-235.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Autor: Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2013 Oct; Vol. 123 (10), pp. 4144-57. Date of Electronic Publication: 2013 Sep 03.